A new organocatalytic asymmetric domino Michael/O-alkylation reaction of maleimides with g-halogenated-b-ketoesters catalyzed by simple, cheap, and commercially available quinine is described.
A new organocatalytic asymmetric domino Michael/O-alkylation reaction of maleimides with g-halogenated-b-ketoesters catalyzed by simple, cheap, and commercially available quinine is described.
The substrates are also commercially available. A variety of new chiral succinimide substituted 3(2H)-furanones were obtained in high yields (up to 94%) and good enantioselectivities (up to 94% ee).
The absolute configuration of the new compound 4f was determined by single-crystal X-ray analysis and the proposed reaction pathway is also shown.
3(2H)-Furanones are core structural motifs that are widely present in many natural products and medicinally important agents.
1 3(2H)-Furanone derivatives exhibit a wide range of biological activities such as antiulcer, 2 antitumor, 3 antiallergic, 4 antiproliferactive, 5 selective MAO-B inhibitory 6 and selective COX-2 inhibitory 7 activities. A variety of approaches toward the synthesis of achiral 3(2H)-furanones have been established, including metal-free processes 8 as well as transition-metalcatalyzed cyclizations. 9 However, protocols to construct chiral 3(2H)-furanone derivatives have been less studied. Marson and coworkers reported Sharpless's asymmetric dihydroxylation followed by a cyclization sequence of enynones to synthesize chiral 3(2H)-furanones. 10 Jing and coworkers reported asymmetric Michael addition of simple 3(2H)-furanones to a,b-unsaturated ketones catalyzed by a cinchona-based tertiaryprimary diamine catalyst 11 or a,b-unsaturated aldehydes catalyzed by diphenylprolinol silyl ether 12 to construct complex chiral 3(2H)-furanones. These reactions require harsh reaction conditions or specic substrates and complex chiral catalysts. Recently, g-halogenated-b-ketoesters, which are commercially available, are used to construct chiral 3(2H)-furanones with imines 13 and chain nitroalkenes 14 via domino reactions. 15 This synthetic strategy is efficient and mild. However, these reactions also need complex chiral catalysts such as tertiary amine squaramide, 13a tertiary amine thiourea 13b,14a and 6 0 -demethyl quinine catalysts. 14b Moreover, the substrate scope is relatively limited. For the signicance of chiral 3(2H)-furanones, it is strongly useful and desirable to discover other appropriate electrophiles such as cyclic alkenes to react with g-halogenatedb-ketoesters catalyzed by simple, cheap, commercially available catalysts to construct diverse chiral substituted 3(2H)-furanones. Maleimides, which are also commercially available, are an important class of cyclic alkenes. They have been extensively applied in asymmetric organocatalysis to construct chiral succinimide derivatives, which are core structural units found in natural products and clinical drug candidates. 16 To date, there has been no report of asymmetric reaction of g-halogenatedb-ketoesters with maleimides, which could afford a new class of chiral products combining biologically signicant succinimides with 3(2H)-furanones. These fused chiral products might show higher or new biological activities. Recently, we reported the same transformation in racemic version catalyzed by Et 3 N.
17 As a part of our continuing interests in the construction of more complex and novel drug candidates, 18 herein, we wish to report the rst asymmetric domino Michael/O-alkylation reaction of g-halogenated-b-ketoesters with maleimides catalyzed by simple, cheap, commercially available cinchona alkaloids to access a new range of chiral succinimide substituted 3(2H)-furanones ( Fig. 1 ). Córdova and coworkers reported asymmetric domino Michael/a-alkylation reaction of g-halogenatedb-ketoesters with a,b-unsaturated aldehydes to afford cyclopentanone products. 19 This report shows variable chemical reactivities of g-halogenated-b-ketoesters with activated alkenes. Our preliminary studies involved maleimide 1a and ethyl 4-bromo-acetoacetate 2a as substrates, these were allowed to react in the presence of 20 mol% cinchonine with 100 mol% Na 2 CO 3 in CH 2 Cl 2 at room temperature. The reaction worked well and gave succinimide substituted 3(2H)-furanone 4a in 85% yield and 68% ee via domino Michael/O-alkylation process not Michael/a-alkylation process (Scheme 1).
To evaluate the reactivity of this catalytic system, the reaction of N-phenyl maleimide 1a with ethyl 4-bromo-acetoacetate 2a was used as a model reaction, and four kinds of natural cinchona alkaloid catalysts were investigated in CH 2 Cl 2 at room temperature ( Table 1 , entries 1-4). All catalysts gave good yields, quinine afforded best enantioselectivity than other catalysts and was chosen as the most suitable catalyst for further optimazation ( To further optimize the reaction conditions, reaction temperature was investigated ( Table 2, entries 1-4) . Decreasing reaction temperature increased enantioselectivities but slowed down the reaction rate. Aer reaction for 24 h, good yield could still be obtained at 0 C (Table 2 , entry 2), but further lowering the reaction temperature, the yields decreased obviously ( Table 2 , entries 3 and 4). 0 C was the optimal reaction temperature. Then we examined the effect of catalyst loadings. Decreasing catalyst loadings to 10 mol% still gave good yield and enantioselectivity (Table 2 , entry 5). We next examined the effect of molar ratio, increasing or lowering the molar ratio slightly inuenced the yields and slightly decreased the enantioselectivities (Table 2 , entries 6 and 7). The substrate concentration was also examined. It was found that increasing or lowering the substrate concentration slightly decreased the yields and enantioselectivities ( Table 2 , entries 8 and 9). Consequently, the following reaction conditions were recommended: 10 mol% quinine, 1 equivalent of Na 2 CO 3 with 0.2 M of substrate concentration in CHCl 3 at 0 C.
Under the optimal reaction conditions, the generality of this protocol was studied (Table 3) . Firstly, a wide range of N-aromatic and aliphatic maleimides 1a-m were studied (Table  3 , entries 1-13). All gave good yields and moderate to good enantioselectivities (80-94% yield, 68-94% ee). N-phenyl maleimides with strong electron-withdrawing nitro group 1g and 1i gave slightly lower yields and enantioselectivities (Table 3 , entries 7 and 9). For N-aliphatic maleimides, good yields and enantioselectivities could still be obtained (Table 3 , entries 11-13) and N-benzyl maleimide gave best enantioselectivity (91% yield, 94% ee, Table 3 , entry 13). In addition, methyl 4-chloroacetoacetate 2b and ethyl 4-bromoacetoacetate 2c were also tested, both provided good yields and enantioselectivities (Table 3 , entries 14 and 15). The absolute conguration was determined by an X-ray analysis of the single crystal of 4f, which was assigned as (S) (Fig. 2) .
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Based on the experimental results and the observed congu-ration of 4f, a plausible mechanism is proposed in Scheme 2. The tertiary amine group of quinine catalyst activates 4-bromoacetoacetate in its enol form and the hydroxyl moiety activates maleimide through hydrogen bonding, thus the enolate would attack the maleimide from Re face via transition state TS (Scheme 2). Through the dual activation of quinine catalyst, Michael reaction is realized and generates intermediary Michael adduct A. Then in the presence of Na 2 CO 3 , intermediary Michael adducts A forms enolate ion 4a 0 , which undergoes an intramolecular O-alkylation process to form the product 4a with (S)-conguration.
Conclusions
In summary, we have developed a new organocatalytic asymmetric domino Michael/O-alkylation reaction of maleimides with g-halogenated-b-ketoesters catalyzed by simple, cheap, and commercially available quinine. The substrates are also commercially available. A wide range of new chiral succinimide substituted 3(2H)-furanones were smoothly obtained in high yields (up to 94%) and good enantioselectivities (up to 94% ee). Further, expansion of these new succinimide substituted 3(2H)-furanones to access products with known biological activities or new biologically signicant molecules and testing their pharmacological activities are ongoing in our laboratory.
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